Casablanca

Researchers are evaluating the quality of primary healthcare systems for patients with arterial hypertension (HTA) in Morocco, focusing on its high prevalence and impact on illness and death rates. The study aims to understand different types of hypertension, related complications, and how blood pressure is managed across the country. It also seeks to compare current practices with past data and European clinical guidelines to improve prevention and treatment strategies. This observational study uses an electronic registry to collect anonymous medical data from primary care and hospital settings. Trained investigators will standardize blood pressure measurements to ensure accuracy. Data collected will include patient height, weight, waist size, blood pressure readings using validated devices, and metabolic tests like blood glucose and cholesterol levels. Information about cardiovascular complications will also be recorded. The study follows a cohort design with a cross-sectional view and plans to track patients for one year. Participants will provide informed consent to include their information in the registry. Researchers will analyze prevalence, hypertension types, and geographic distribution within Morocco. They will also compare findings with previous years and other North African countries. The study monitors blood pressure control, treatment patterns, complications, and metabolic health. These results aim to identify gaps and improvements in primary care for hypertension, helping to enhance patient management and outcomes over the 2024-2026 period.

Researchers are evaluating the safety and efficacy of DCR-PHXC in people with Primary Hyperoxaluria Type 1 (PH1) who have severe kidney impairment, including those on dialysis. This Phase 2, open-label study aims to better understand how DCR-PHXC works in this group of patients, as they often face serious kidney problems due to their condition. Participants will receive monthly doses of DCR-PHXC during the initial treatment period, which lasts up to 180 days following a screening period of up to 35 days. Those who complete this phase successfully may continue treatment for up to 5 additional years in an extended follow-up phase. During this extended period, visits to the clinic occur every three months, and participants or their caregivers may be trained to administer DCR-PHXC at home or receive help from home health nurses. Throughout the study, participants will have regular clinic visits for dosing and monitoring. Assessments will include safety checks and tracking any side effects for up to 180 days as the primary outcome. The total study duration is about 5 years from the first participant's initial visit to the last participant's Day 180 visit, with ongoing monitoring during the extended follow-up to ensure safety and evaluate long-term effects.

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, with increasing prevalence in Morocco. Between 2010 and 2012, the "All with heart" Association conducted a large cardiovascular screening involving over 10,000 adults aged 40 and older in the Greater Casablanca region. This study aims to follow up on these participants 10 years later to evaluate long-term cardiovascular outcomes and to develop a risk score specific to the Moroccan population. The study involves contacting participants or their families through phone calls, WhatsApp, or SMS to collect follow-up data on cardiovascular deaths, heart attacks, and strokes. Statistical methods such as survival analysis and multivariate logistic regression will be used to identify key risk factors and to create a predictive model tailored for Morocco. Participants or their families provide written informed consent before data collection. During the study, researchers will gather information on major cardiovascular events over the 10-year period since initial screening. The main outcomes include the incidence of these events and the validation of the Morocco-specific cardiovascular risk score. The study has ethical approval from the Rabat Ethics Committee and aims to improve understanding of cardiovascular risk evolution and support prevention and management strategies in Morocco.